MiNK Therapeutics Aktie
WKN DE: A3C5HZ / ISIN: US6036931029
11.07.2025 18:23:41
|
MiNK Therapeutics Stock Skyrockets 643% On Cancer Remission Case
(RTTNews) - MiNK Therapeutics, Inc. (INKT) shares surged 643.52 percent to $57.47 after the publication of a breakthrough case study in Nature's Oncogene highlighted a complete and lasting remission in a patient with advanced testicular cancer treated with the company's iNKT cell therapy, agenT-797.
Shares opened at $21.07 and soared as high as $58.50 on extreme volume of 25.9 million, compared to an average of just 7,585 on the Nasdaq. The stock now sits at the upper end of its 52-week range of $4.56 to $58.50.
The patient had previously failed multiple therapies, including chemotherapy and checkpoint inhibitors, but achieved full remission with a single infusion combined with nivolumab—remaining disease-free for over two years.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu MiNK Therapeutics Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |